Literature DB >> 7952116

Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry.

D S Mautz1, R Labroo, E D Kharasch.   

Abstract

This report describes a simple gas chromatographic-mass spectrometric (GC-MS) assay for the simultaneous analysis of alfentanil and its major metabolite, noralfentanil, in human plasma. The method facilitates the processing of numerous samples for pharmacokinetic analysis. Alfentanil and noralfentanil are extracted from plasma under basic conditions and noralfentanil is converted to the pentafluoropropionyl derivative. The extraction efficiencies for noralfentanil and alfentanil were > 99% and 70%, respectively. Standard curves were linear (r2 = 0.99) over the ranges of 5-500 ng/ml for alfentanil and 0.4-10 ng/ml for noralfentanil. Inter-day coefficients significant improvement over existing HPLC assays which require radiolabelled significant improvement over existing HPLC assays which require radiolabelled alfentanil. The simultaneous disposition of alfentanil and noralfentanil in plasma after intravenous administration in humans is described.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7952116     DOI: 10.1016/0378-4347(94)00201-0

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  2 in total

1.  Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.

Authors:  Nariné Baririan; Luc Van Obbergh; Jean-Pierre Desager; Roger K Verbeeck; Pierre Wallemacq; Peter Starkel; Yves Horsmans
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry.

Authors:  Thomas Kim; Amy London; Evan D Kharasch
Journal:  J Pharm Biomed Anal       Date:  2011-03-05       Impact factor: 3.935

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.